| Title |
|
Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
| Type of document |
|
| OrcId |
|
| DOI |
|
| Abstract |
|
Advanced chronic liver disease is an increasing cause of premature morbidity and mortality in the UK. Portal hypertension is the primary driver of decompensation, including the development of ascites, hepatic encephalopathy and variceal haemorrhage. Non-selective beta blockers (NSBB) reduce portal pressure and are well established in the prevention of variceal haemorrhage. Carvedilol, a newer NSBB, is more effective at reducing portal pressure due to additional α-adrenergic blockade and has additional anti-oxidant, anti-inflammatory and anti-fibrotic effects. |
|
|
| Link |
|
| Citation |
|
Alimentary Pharmacology & Therapeutics 2023; 57(5) |
|
|
| Jornal Title |
|
Alimentary Pharmacology & Therapeutics |
|
|
| ISSN |
|
